Aortic Valve (TAVR/TAVI)Friday, May 29, 2026
Josh Brown's 'best stocks in the market': Edwards Lifesciences - CNBC
1 min read·By E. Nolan Beckett, MD·Source: CNBC
From The Valve Wire
The LANDMARK 2-year readout extends Myval (Meril Life Sciences) noninferiority versus SAPIEN and Evolut on the composite of death, stroke, and valve-related hospitalization.
The 1-year arms overlapped at 87.0% versus 86.9% freedom from events; the 2-year curve, per TCTMD's coverage, continues to track that pattern.
Editor’s take pending for this article; this is the section commentary excerpt.
Source Abstract
Josh Brown's 'best stocks in the market': Edwards Lifesciences CNBC
Read the Original
Full article at CNBC
Open at CNBC →The Valve Wire summarizes; we link out to primary sources for verification.
More in Aortic Valve (TAVR/TAVI)
- Aortic Valve (TAVR/TAVI)· TCTMD.comLANDMARK: 2-Year Data Show Continued Safety and Efficacy of Unique TAVI Valve - TCTMD.com
- Aortic Valve (TAVR/TAVI)· Cardiovascular BusinessThe high costs of robotic tech | Medtronic recalls thousands of devices | TAVR in younger patients | FDA approves next-gen valve - Cardiovascular Business
- Aortic Valve (TAVR/TAVI)· Investing.com AustraliaEdwards Lifesciences CVP Donald Bobo Jr. sells $2m in stock - Investing.com Australia
Elsewhere in Today’s Issue
- Clinical Trials Update· ClinicalTrials.govREdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
- Clinical Trials Update· ClinicalTrials.govReal World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation
- Clinical Trials Update· ClinicalTrials.govNHLBI-Emory Advanced Cardiac CT Reconstruction